Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of KLH-2109 in uterine fibroids with menorrhagia and pain
jRCT2031220181Phase 3Completed
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Fibromyoma (LM) comparing KLH-2109 with Placebo (2 arms). Primary endpoints: Proportion of subjects with very low menstrual blood loss (Week 6-12) and Proportion of subjects with minimal pain (last 28 days of treatment). Started Jun 2022; status: completed.
02
Drugs
linzagolix
03
Conditions
Fibromyoma (LM)
Beyond the preview
Go deeper on jRCT2031220181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220181.